Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MannKind Corporation - Common Stock
(NQ:
MNKD
)
2.700
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 21, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
430
Open
2.700
Bid (Size)
2.760 (1,000)
Ask (Size)
2.850 (100)
Prev. Close
2.700
Today's Range
2.700 - 2.700
52wk Range
2.230 - 6.510
Shares Outstanding
264,305,532
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
March 09, 2026
From
MannKind
Via
GlobeNewswire
MannKind Announces Settlement of Convertible Senior Notes
March 05, 2026
From
MannKind
Via
GlobeNewswire
Performance
YTD
-51.8%
-51.8%
1 Month
+10.7%
+10.7%
3 Month
-50.8%
-50.8%
6 Month
-51.0%
-51.0%
1 Year
-39.2%
-39.2%
More News
Read More
MannKind to Participate in Upcoming Investor Conferences
March 04, 2026
From
MannKind
Via
GlobeNewswire
What's Going On With MannKind Stock Friday?
↗
February 27, 2026
Via
Benzinga
MannKind Corp (NASDAQ:MNKD) Reports Q4 2025 Revenue Beat and Strategic Outlook for 2026
↗
February 26, 2026
Via
Chartmill
MannKind Rallies On Optimism Of Two Imminent Product Launches: Analyst Sees ‘Multiple Headwinds’ For Stock In 2026
↗
January 08, 2026
Via
Stocktwits
MannKind Stock Slips Despite FDA Clearing Pediatric Use Of Heart Failure Drug — What’s Spooking Investors?
↗
December 23, 2025
Via
Stocktwits
Why MannKind Stock Tumbled on Thursday
↗
February 26, 2026
Via
The Motley Fool
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026
From
MannKind
Via
GlobeNewswire
Let's take a look at the stocks that are in motion in today's session.
↗
February 25, 2026
Via
Chartmill
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’
↗
February 25, 2026
Via
Stocktwits
Here are the top movers in Wednesday's session.
↗
February 25, 2026
Via
Chartmill
The market is filled with gapping stocks in Wednesday's session.
↗
February 25, 2026
Via
Chartmill
MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 19, 2026
From
MannKind
Via
GlobeNewswire
MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
February 18, 2026
From
MannKind
Via
GlobeNewswire
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
February 09, 2026
From
MannKind
Via
GlobeNewswire
Why Did MNKD Stock Jump Over 7% In Pre-Market Today?
↗
January 26, 2026
Via
Stocktwits
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
January 26, 2026
From
MannKind
Via
GlobeNewswire
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
January 23, 2026
From
Equity Insider
Via
GlobeNewswire
MannKind Provides Business Updates and 2026 Growth Drivers
January 08, 2026
From
MannKind
Via
GlobeNewswire
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares?
↗
December 24, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
Why a Fund Trimmed an $18 Million Stake in Primo Brands Amid a 47% Stock Drop
↗
December 23, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
Lantheus Exit: $28 Million Sale Comes as Earnings Fall 77% Year Over Year
↗
December 23, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
Supply Chain
MannKind Shares FUROSCIX® Business Updates
December 23, 2025
From
MannKind
Via
GlobeNewswire
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
December 01, 2025
From
MannKind
Via
GlobeNewswire
Frequently Asked Questions
Is MannKind Corporation - Common Stock publicly traded?
Yes, MannKind Corporation - Common Stock is publicly traded.
What exchange does MannKind Corporation - Common Stock trade on?
MannKind Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MannKind Corporation - Common Stock?
The ticker symbol for MannKind Corporation - Common Stock is MNKD on the Nasdaq Stock Market
What is the current price of MannKind Corporation - Common Stock?
The current price of MannKind Corporation - Common Stock is 2.700
When was MannKind Corporation - Common Stock last traded?
The last trade of MannKind Corporation - Common Stock was at 04/21/26 04:00 PM ET
What is the market capitalization of MannKind Corporation - Common Stock?
The market capitalization of MannKind Corporation - Common Stock is 713.62M
How many shares of MannKind Corporation - Common Stock are outstanding?
MannKind Corporation - Common Stock has 714M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
